/ LLY
/ Market Analysis
Why are Verve Therapeutics Shares Skyrocketing in Premarket Trading Today?
Eli Lilly is reportedly close to acquiring gene editing partner Verve Therapeutics for up to $1.3 billion.
June 17, 2025
NVO vs LLY: Which Pharma Stock is Likely to Do Better in 2025?
Obesity market continues to boom, with Novo Nordisk opening the gates wide open with Wegovy.
May 13, 2025
Eli Lilly’s Stock Tumbles as Firm Cuts EPS Guidance Despite Strong Q1
Eli Lilly's stock dropped over 7% after announcing a lowered profit forecast, despite exceeding Q1 expectations.
May 01, 2025
Eli Lilly’s Stock Soars After Weight-Loss Pill Competing with Ozempic Shows Promise
Eli Lilly's new weight-loss pill, matches Ozempic in effectiveness.
April 17, 2025
Eli Lilly’s Q4 2024 Revenue Surges by 45% to $13.53 Billion
Eli Lilly and Company (NYSE: LLY) reported a robust revenue growth of 45% in Q4 2024, reaching $13.53 billion, driven by increased volume from key products.
February 06, 2025More from The Tokenist / LLY
LLY Stock Rebounds Amid AI-Driven ALS Research Breakthroughs
November 20, 2024
Stocks to Watch Today: Tesla, LLY, and Bank of America
August 20, 2024
Stocks to Watch Today: LLY, WBD, and AMAT
August 08, 2024
Stocks to Watch Today: CCL, LLY, and DLTR
June 25, 2024
Back to 
